Head & Neck Cancers | Specialty

Dr. Weiss on Immunotherapy Combinations in Head and Neck Cancer

July 25th 2017

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses immunotherapy combinations in head and neck cancer.

Dr. Cohen Discusses NK-Directed Therapy in Head and Neck Cancer

July 25th 2017

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses natural killer-directed therapy in head and neck cancer.

Pembrolizumab Falls Short in Phase III Head and Neck Cancer Trial

July 25th 2017

Pembrolizumab (Keytruda) did not meet the primary endpoint of overall survival in the phase III KEYNOTE-040 trial in patients with previously-treated recurrent or metastatic head and neck squamous cell carcinoma.

Expert Discusses Key Immunotherapy Trials and Next Steps in Head and Neck Cancer

July 21st 2017

Joshua Bauml, MD, discusses the current role of immunotherapy in this disease, potential next steps, and unmet needs in HPV-associated head and neck cancer.

Dr. Burtness on Combinations of Immunotherapy in Head and Neck Cancer

July 21st 2017

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses immunotherapy combinations for patients with head and neck cancer.

Dr. Cohen on CAR T-Cell Therapy for Head and Neck Cancer

July 20th 2017

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses CAR T-cell therapy for patients with head and neck cancer.

Dr. Burtness on Immunotherapy and Radioresistance in Head and Neck Cancer

July 19th 2017

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses immunotherapy in patients with head and neck cancer who have radioresistance.

Dr. Weiss Discusses Current Clinical Trials in Head and Neck Cancer

July 19th 2017

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses current clinical trials in head and neck cancer.

Expert Discusses Evolving Treatment Options in Head and Neck Cancer

July 19th 2017

Jared Weiss, MD, discusses the evolving role of immunotherapy and other promising developments in head and neck cancer.

Dr. Bauml Discusses Immunotherapy in Head and Neck Cancer

July 19th 2017

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses immunotherapy in head and neck cancer.

Cohen Discusses Immunotherapy Combos, CAR T-Cell Therapy in HNSCC

July 18th 2017

Ezra Cohen, MD, discusses anti–PD-1/PD-L1 combination regimens in HNSCC, the potential for CAR T-cell therapy, and remaining challenges with immunotherapy in the field.

Dr. Cohen Discusses Immunotherapy Combinations in Head and Neck Cancer

July 18th 2017

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses immunotherapy combinations in head and neck cancer.

Nivolumab Associated With Improved QoL in Head and Neck Cancer

July 13th 2017

Following treatment with single-agent nivolumab (Opdivo), patients with head and neck squamous cell carcinoma saw improved or stable quality of life scores.

Dr. Siegel on Results of Chemotherapy and Transoral Surgery Study for Head and Neck Cancer

July 11th 2017

Robert Siegel, MD, chair, professor of medicine, director, Division of Hematology/Oncology, George Washington University, discusses a phase II study investigating induction chemotherapy and transoral surgery for patients with head and neck cancer.

Dr. Siegel on the Treatment of HPV-Associated Head and Neck Cancer

July 7th 2017

Robert Siegel, MD, chair, professor of medicine, director, Division of Hematology/Oncology, George Washington University, discusses the treatment for patients with HPV-associated head and neck cancer.

Future Directions in Treating HNSCC

July 7th 2017

Emerging Agents to Treat HNSCC

July 7th 2017

Predictive Biomarkers in HNSCC

July 7th 2017

Patient Selection in Treating HNSCC

July 7th 2017

Nivolumab in HNSCC

July 7th 2017